Alnylam Pharmaceuticals Inc. (ALNY)

87.13
2.40 2.80
NASDAQ : Health Technology
Prev Close 84.77
Open 85.03
Day Low/High 84.99 / 87.27
52 Wk Low/High 60.27 / 110.00
Volume 508.01K
Avg Volume 694.70K
Exchange NASDAQ
Shares Outstanding 111.21M
Market Cap 9.25B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Alnylam Announces New RNAi Therapeutic Program For The Treatment Of Hepatitis B Virus (HBV) Infection And Reports An Up To 2.3 Log10 Reduction Of HBV Surface Antigen (HBsAg) In Chronically Infected Chimpanzees

Alnylam Announces New RNAi Therapeutic Program For The Treatment Of Hepatitis B Virus (HBV) Infection And Reports An Up To 2.3 Log10 Reduction Of HBV Surface Antigen (HBsAg) In Chronically Infected Chimpanzees

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has named a new program to its pipeline: ALN-HBV for the treatment of hepatitis B virus (HBV) infection.

Alnylam Presents Key Scientific Data On Enhanced Stabilization Chemistry (ESC)-GalNAc-Conjugate Technology

Alnylam Presents Key Scientific Data On Enhanced Stabilization Chemistry (ESC)-GalNAc-Conjugate Technology

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it is presenting key scientific data on its Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate delivery ...

Alnylam Pharmaceuticals Reports First Quarter 2014 Financial Results And Highlights Recent Period Activities

Alnylam Pharmaceuticals Reports First Quarter 2014 Financial Results And Highlights Recent Period Activities

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2014, and company highlights.

Alnylam To Webcast Presentation At Bank Of America Merrill Lynch 2014 Health Care Conference

Alnylam To Webcast Presentation At Bank Of America Merrill Lynch 2014 Health Care Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Bank of America Merrill Lynch 2014 Health Care...

Alnylam Advances Development Candidate For ALN-AAT, A Subcutaneously Administered RNAi Therapeutic Targeting Alpha-1 Antitrypsin (AAT) In Development For The Treatment Of AAT Deficiency-Associated Liver Disease

Alnylam Advances Development Candidate For ALN-AAT, A Subcutaneously Administered RNAi Therapeutic Targeting Alpha-1 Antitrypsin (AAT) In Development For The Treatment Of AAT Deficiency-Associated Liver Disease

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate (DC) for ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin ...

Alnylam To Webcast Conference Call Discussing First Quarter 2014 Financial Results

Alnylam To Webcast Conference Call Discussing First Quarter 2014 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the first quarter ending March 31, 2014 on Thursday, May 8, 2014, after the...

Alnylam Presents New Pre-clinical Data On Subcutaneously Delivered RNAi Therapeutics For Cardiovascular Metabolic Disease At Arteriosclerosis, Thrombosis And Vascular Biology 2014 Scientific Sessions

Alnylam Presents New Pre-clinical Data On Subcutaneously Delivered RNAi Therapeutics For Cardiovascular Metabolic Disease At Arteriosclerosis, Thrombosis And Vascular Biology 2014 Scientific Sessions

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from RNAi therapeutic programs toward genetically validated targets in ...

Alnylam To Webcast Presentation At Deutsche Bank 39th Annual Health Care Conference

Alnylam To Webcast Presentation At Deutsche Bank 39th Annual Health Care Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Deutsche Bank 39 th Annual Health Care Conference on ...

Alnylam Presents New Pre-clinical Data On RNAi Therapeutics Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR)

Alnylam Presents New Pre-clinical Data On RNAi Therapeutics Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the presentation of new pre-clinical data on RNAi therapeutics targeting transthyretin (TTR) for the treatment of ...

Today's Dead Cat Bounce Stock Is Alnylam Pharmaceuticals (ALNY)

Today's Dead Cat Bounce Stock Is Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate

Alnylam And Collaborators Present New Clinical Data For Patisiran, An RNAi Therapeutic Targeting Transthyretin (TTR) In Development For The Treatment Of TTR-Mediated Amyloidosis (ATTR)

Alnylam And Collaborators Present New Clinical Data For Patisiran, An RNAi Therapeutic Targeting Transthyretin (TTR) In Development For The Treatment Of TTR-Mediated Amyloidosis (ATTR)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and collaborators announced today new clinical data for patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) ...

Biotech M&A is MIA

Biotech M&A is MIA

Healthcare M&A activity is booming but expensive, risky biotech stocks are left on the sidelines.

Commit To Purchase Alnylam Pharmaceuticals At $40, Earn 18.3% Annualized Using Options

Commit To Purchase Alnylam Pharmaceuticals At $40, Earn 18.3% Annualized Using Options

Investors eyeing a purchase of Alnylam Pharmaceuticals shares, but tentative about paying the going market price of $51.30/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $40 strike, which has a bid at the time of this writing of $4.80.

Why Alnylam Pharmaceuticals (ALNY) Stock is Down Today

Why Alnylam Pharmaceuticals (ALNY) Stock is Down Today

Alnylam Pharmaceuticals (ALNY) dipped Monday amid reports that Novartis (NVS) is closing a significant portion of its RNAi research endeavors in Boston. FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems in delivering such therapies tied to the limited number of potential relevant targets led to the move. "We have decided to significantly reduce our internal drug discovery efforts in RNA therapeutics," Novartis told FierceBiotech in a statement. "This decision was driven by ongoing challenges with formulation and delivery and the reality that the current range of medically relevant targets where siRNA may be used is quite narrow. In the future we will have a small group working in this field and look for partnering opportunities." Alnylam suffered in the wake of the news, as Novartis' program emerged from a partnership with Alnylam, one of the leaders in the RNAi drug development field. The stock fell more than 4.5% to a low of $52.02 for the day as of 3:12 p.m. on Monday.

Alnylam Pharmaceuticals (ALNY) Showing Signs Of A Dead Cat Bounce Today

Alnylam Pharmaceuticals (ALNY) Showing Signs Of A Dead Cat Bounce Today

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate

Alnylam’s McSwiggen Patent Upheld In European Opposition Proceedings

Alnylam’s McSwiggen Patent Upheld In European Opposition Proceedings

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has upheld the McSwiggen EP 1423406 (’406) patent in oral opposition ...

Alnylam To Webcast Presentation At 13th Annual Needham Healthcare Conference

Alnylam To Webcast Presentation At 13th Annual Needham Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 13 th Annual Needham Healthcare Conference on Wednesday,...

Alnylam Receives Positive Opinion For Orphan Drug Designation In The European Union For ALN-TTRsc, A Subcutaneously Delivered RNAi Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis (ATTR)

Alnylam Receives Positive Opinion For Orphan Drug Designation In The European Union For ALN-TTRsc, A Subcutaneously Delivered RNAi Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis (ATTR)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive ...

Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)

Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate

Genzyme Exercises Its Right To Purchase Additional Shares Of Alnylam Common Stock

Genzyme Exercises Its Right To Purchase Additional Shares Of Alnylam Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that Genzyme, a Sanofi company, has exercised its right to purchase 344,448 unregistered shares of Alnylam’s...

Alnylam To Present Data From Its RNAi Therapeutic Programs Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR) At XIVth International Symposium On Amyloidosis (ISA)

Alnylam To Present Data From Its RNAi Therapeutic Programs Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR) At XIVth International Symposium On Amyloidosis (ISA)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that its scientists and collaborators will present pre-clinical and clinical data with patisiran (ALN-TTR02) and ...

Alnylam To Webcast Presentation At Barclays Global Healthcare Conference

Alnylam To Webcast Presentation At Barclays Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 13,...

Alnylam Announces Closing Of Previously Announced Acquisition Of Merck’s Sirna Therapeutics Subsidiary

Alnylam Announces Closing Of Previously Announced Acquisition Of Merck’s Sirna Therapeutics Subsidiary

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the previously announced acquisition of Merck’s wholly owned subsidiary Sirna Therapeutics, Inc.

Alnylam Announces Closing Of Previously Announced Alliance With Genzyme For Discovery, Development, And Commercialization Of RNAi Therapeutics As Genetic Medicines

Alnylam Announces Closing Of Previously Announced Alliance With Genzyme For Discovery, Development, And Commercialization Of RNAi Therapeutics As Genetic Medicines

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the previously announced alliance with Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) has closed, ...

Alnylam To Webcast Presentation At Cowen And Company 34th Annual Health Care Conference

Alnylam To Webcast Presentation At Cowen And Company 34th Annual Health Care Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Cowen and Company 34 th Annual Health Care Conference on...

Alnylam: Biotech on the Verge of a Breakout

Alnylam: Biotech on the Verge of a Breakout

Alnylam was rising on unusual volume on Thursday. Here's how to trade it today.

Alnylam Pharmaceuticals Larger Than S&P 500 Component PerkinElmer

Alnylam Pharmaceuticals Larger Than S&P 500 Component PerkinElmer

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Alnylam Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example PerkinElmer, Inc. , according to The Online Investor.

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results And Highlights Recent Period Activities

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results And Highlights Recent Period Activities

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2013, and company highlights.

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2013 Financial Results

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2013 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the fourth quarter and year ending December 31, 2013 on Thursday, February ...

Insider Trading Alert - POWI, ALNY, LLL, TAL And MDP Traded By Insiders

Insider Trading Alert - POWI, ALNY, LLL, TAL And MDP Traded By Insiders

Stocks with insider trader activity include POWI, ALNY, LLL, TAL and MDP